Guidelines: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 43: | Line 43: | ||
* [[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]] | * [[AUA: Management of LUTS Attributed to BPH (2021)|Management of LUTS Attributed to BPH (2021)]] | ||
*[[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]] | *'''<span style="color:#008000">NEW!</span>''' [[AUA: Overactive Bladder (2019)|Overactive Bladder (2019)]] | ||
*[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]] | *[[AUA & CUA Mesh Position Statement (2019)|AUA/CUA Mesh Position Statement (2019)]] | ||
* [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]] | * [[AUA: Incontinence after Prostate Therapy (2019)|Incontinence after Prostate Therapy (2019)]] | ||